Início › Câncer de Ovário › Colorado › Denver
Ensaios clínicos de Câncer de Ovário em Denver, CO
16 estudos para Câncer de Ovário estão buscando participantes em locais em Denver e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
The Vanguard Study: Testing a New Way to Screen for Cancer
RecrutandoVoluntários saudáveis bem-vindos
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
RecrutandoFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecrutandoFase 1
- Sarah Cannon Research Institute at HealthOne, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecrutandoFase 1/2
- Rocky Mountain Cancer Center, Denver
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecrutandoFase 1
- SCRI at HealthOne, Denver
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
RecrutandoFase 1
- Sarah Cannon Research Institute at HealthONE /ID# 278785, Denver
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecrutandoFase 3
- AdventHealth Medical Group - Porter, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
RecrutandoFase 1/2
- SCRI at HCA Health One, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RecrutandoFase 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecrutandoFase 1
- Normunity Investigational Site, Denver
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecrutandoFase 3
- Cancer Center of Colorado at Sloan's Lake, Denver
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
RecrutandoFase 1/2
- Research Site, Denver
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
RecrutandoFase 1
- Sarah Cannon Research Institute at HealthONE, Denver
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RecrutandoFase 1
- Dren Investigational Site, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Denver
Ensaios de Câncer de Ovário em outras cidades
- Houston, TX89 estudos
- New York City, NY69 estudos
- Boston, MA61 estudos
- Los Angeles, CA50 estudos
- Nashville, TN49 estudos
- Arlington, VA46 estudos
- Philadelphia, PA44 estudos
- Columbus, OH39 estudos
- St. Louis, MO38 estudos
- Chicago, IL36 estudos
- San Antonio, TX31 estudos
- Cleveland, OH30 estudos
Outros estudos em Denver
- Câncer Metastático29 estudos
- Câncer de Mama29 estudos
- Câncer de Pulmão de Não Pequenas Células27 estudos
- Mieloma Múltiplo27 estudos
- Câncer Colorretal23 estudos
- Melanoma19 estudos
- Câncer de Próstata19 estudos
- Câncer (todos os tipos)18 estudos
- Câncer de Pulmão16 estudos
- Câncer Endometrial15 estudos
- Linfoma Não Hodgkin14 estudos
- Câncer de Pâncreas13 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.